Serotonin–norepinephrine–dopamine reuptake inhibitor

A serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI), also known as a triple reuptake inhibitor (TRI or TUI), is a type of drug that acts as a combined reuptake inhibitor of the monoamine neurotransmitters serotonin, norepinephrine, and dopamine, resulting in increased signaling in associated neurological systems.

SNDRIs were developed as potential antidepressants and treatments for other disorders, such as obesity, cocaine addiction, attention deficit hyperactivity disorder (ADHD), and chronic pain. The goal of such development was improved efficacy or tolerability over existing selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine reuptake inhibitors (SNRIs), and dopamine–norepinephrine reuptake inhibitors (NDRIs). However, increased side effects and abuse potential are concerns when using these agents, relative to their more selective counterparts.

SNDRIs include the naturally occurring drug cocaine, a widely used recreational and often illegal drug for the euphoric effects it produces. Additionally, MDMA, another common drug of abuse, is also an SNDRI, however its reuptake inhibition is comparatively weak compared to its properties as a serotonin–dopamine–norepinephrine releasing agent.